SAVA · Cassava Sciences Inc

-

Please sign in to comment on SAVA

1 Comment

Admin

4 years ago

Cassava Sciences, Inc is currently in a long term uptrend where the price is trading 199.5% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Cassava Sciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 317.8% to $-6M since the same quarter in the previous year.

Finally, its free cash flow fell by 508.2% to $-4M since the same quarter in the previous year.

Based on the above factors, Cassava Sciences, Inc gets an overall score of 2/5.

Sector	Healthcare
Industry	Biotechnology
ISIN	US14817C1071
Exchange	NASDAQ
CurrencyCode	USD

Beta	-1.48
Market Cap	80M
PE Ratio	None
Target Price	2
Dividend Yield	None

ABOUT

Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

SAVA · Cassava Sciences Inc

-

Cassava Sciences Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Cassava Sciences Inc using a moving average strategy